{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ramucirumab+-+SC", "query": { "intervention": "Ramucirumab - SC" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 4, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-07T23:13:39.650Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04495478", "title": "A Study of Ramucirumab (LY3009806) in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Ramucirumab - IV", "type": "DRUG" }, { "name": "Placebo - IV", "type": "DRUG" }, { "name": "Ramucirumab - SC", "type": "DRUG" }, { "name": "Placebo - SC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 50, "start_date": "2020-07-30", "completion_date": "2021-05-09", "has_results": true, "last_update_posted_date": "2023-02-14", "last_synced_at": "2026-09-07T23:13:39.650Z", "location_count": 1, "location_summary": "Daytona Beach, Florida", "locations": [ { "city": "Daytona Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04495478" }, { "nct_id": "NCT05096663", "title": "Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Advanced Lung Non-Small Cell Carcinoma", "Recurrent Lung Non-Small Cell Carcinoma", "Stage III Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Cobalamin", "type": "DIETARY_SUPPLEMENT" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Folic Acid", "type": "DIETARY_SUPPLEMENT" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nogapendekin Alfa", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Ramucirumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG", "BIOLOGICAL" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 82, "start_date": "2022-03-15", "completion_date": "2027-12-01", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-09-07T23:13:39.650Z", "location_count": 350, "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Little Rock, Arkansas + 280 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Arroyo Grande", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05096663" }, { "nct_id": "NCT03281369", "title": "A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma" ], "interventions": [ { "name": "5-Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Ramucirumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "PEGylated recombinant human hyaluronidase (PEGPH20)", "type": "BIOLOGICAL" }, { "name": "BL-8040", "type": "DRUG" }, { "name": "Linagliptin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Tiragolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 219, "start_date": "2017-10-13", "completion_date": "2025-10-09", "has_results": true, "last_update_posted_date": "2026-08-03", "last_synced_at": "2026-09-07T23:13:39.650Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03281369" }, { "nct_id": "NCT04557384", "title": "A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "Ramucirumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2021-02-23", "completion_date": "2021-05-25", "has_results": true, "last_update_posted_date": "2023-02-27", "last_synced_at": "2026-09-07T23:13:39.650Z", "location_count": 4, "location_summary": "Fayetteville, Arkansas • Omaha, Nebraska • Charlotte, North Carolina + 1 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04557384" } ] }